
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/730938/publications.pdf Version: 2024-02-01



RADT VAN HOEK

#	Article	IF	CITATIONS
1	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncology, The, 2009, 10, 35-43.	5.1	1,920
2	Telaprevir for Retreatment of HCV Infection. New England Journal of Medicine, 2011, 364, 2417-2428.	13.9	1,466
3	Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology, 2013, 58, 2045-2055.	3.6	519
4	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infectious Diseases, The, 2016, 16, 685-697.	4.6	402
5	Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma. Transplantation, 2016, 100, 116-125.	0.5	339
6	Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology, 2004, 39, 500-508.	3.6	315
7	Hypothermic Machine Perfusion in Liver Transplantation — A Randomized Trial. New England Journal of Medicine, 2021, 384, 1391-1401.	13.9	305
8	Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1. Gastroenterology, 2014, 147, 443-452.e5.	0.6	268
9	Similar liver transplantation survival with selected cardiac death donors and brain death donors. British Journal of Surgery, 2010, 97, 744-753.	0.1	189
10	Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology, 1992, 15, 215-221.	3.6	187
11	Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. Journal of Hepatology, 2013, 58, 141-147.	1.8	182
12	Protein energy malnutrition predicts complications in liver cirrhosis. European Journal of Gastroenterology and Hepatology, 2011, 23, 982-989.	0.8	170
13	Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + βâ€blocker for prevention of variceal rebleeding. Hepatology, 2016, 63, 581-589.	3.6	168
14	A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort. Journal of Hepatology, 2018, 68, 707-714.	1.8	161
15	Auxiliary versus orthotopic liver transplantation for acute liver failure. Journal of Hepatology, 1999, 30, 699-705.	1.8	157
16	Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology, 1991, 14, 721-729.	3.6	156
17	Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scandinavian Journal of Gastroenterology, 2014, 49, 1245-1254.	0.6	153
18	A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer, 2010, 10, 190.	1.1	146

#	Article	IF	CITATIONS
19	Mannose Binding Lectin Gene Polymorphisms Confer a Major Risk for Severe Infections After Liver Transplantation. Gastroenterology, 2005, 129, 408-414.	0.6	125
20	Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver International, 2011, 31, 92-98.	1.9	117
21	The prognostic value of histology in the assessment of patients with Budd–Chiari syndrome. Journal of Hepatology, 2001, 35, 338-343.	1.8	92
22	mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. Annals of Surgery, 2020, 272, 855-862.	2.1	85
23	Hepatic Allograft Rejection: New Developments in Terminology, Diagnosis, Prevention, and Treatment. Mayo Clinic Proceedings, 1993, 68, 69-79.	1.4	84
24	Extensive chimerism in liver transplants: Vascular endothelium, bile duct epithelium, and hepatocytes. Liver Transplantation, 2003, 9, 552-556.	1.3	77
25	Severe Ductopenic Rejection Following Liver Transplantation: Incidence, Time of Onset, Risk Factors, Treatment, and Outcome. Seminars in Liver Disease, 1992, 12, 41-50.	1.8	76
26	Longterm results of liver transplantation from donation after circulatory death. Liver Transplantation, 2016, 22, 1107-1114.	1.3	71
27	Pharmacokinetics, Efficacy, and Safety of HepatitisÂC Virus Drugs in Patients with Liver and/or Renal Impairment. Drug Safety, 2016, 39, 589-611.	1.4	67
28	Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group. Transplantation, 2009, 88, 614-619.	0.5	64
29	Systematic review with metaâ€analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation. Alimentary Pharmacology and Therapeutics, 2019, 49, 636-643.	1.9	64
30	Lectin complement pathway gene profile of donor and recipient determine the risk of bacterial infections after orthotopic liver transplantation. Hepatology, 2010, 52, 1100-1110.	3.6	61
31	Risk factors for infection after liver transplantation. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 61-72.	1.0	58
32	Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2068-2075.e2.	2.4	55
33	A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation. Journal of Hepatology, 2022, 76, 371-382.	1.8	54
34	Liver transplantation for unresectable hepatocellular carcinoma in normal livers. Journal of Hepatology, 2012, 57, 297-305.	1.8	49
35	Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma. Thrombosis and Haemostasis, 2003, 89, 718-725.	1.8	48
36	Plasma MMP–2 and MMP–9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. Thrombosis and Haemostasis, 2004, 91, 506-513.	1.8	47

#	Article	IF	CITATIONS
37	Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. European Journal of Clinical Investigation, 2012, 42, 760-767.	1.7	46
38	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2018, 67, 1517-1524.	6.1	42
39	Adverse events related to low dose corticosteroids in autoimmune hepatitis. Alimentary Pharmacology and Therapeutics, 2019, 50, 1120-1126.	1.9	42
40	Transjugular Intrahepatic Portosystemic Shunt in Patients With Chronic Portal Vein Occlusion and Cavernous Transformation. Journal of Clinical Gastroenterology, 2009, 43, 982-984.	1.1	41
41	SUCCESSFUL OUTCOME WITH A ???QUINTUPLE APPROACH??? OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER. Transplantation, 2001, 71, 47-52.	0.5	39
42	ASSESSMENT OF SERUM MATRIX METALLOPROTEINASES MMP-2 AND MMP-9 AFTER HUMAN LIVER TRANSPLANTATION: INCREASED SERUM MMP-9 LEVEL IN ACUTE REJECTION. Transplantation, 2004, 77, 1646-1652.	0.5	39
43	Mannose-binding lectin and Ficolin-2 gene polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation. Journal of Hepatology, 2011, 55, 800-807.	1.8	38
44	Acute liver failure, multiorgan failure, cerebral oedema, and activation of proangiogenic and antiangiogenic factors in a case of Marburg haemorrhagic fever. Lancet Infectious Diseases, The, 2012, 12, 635-642.	4.6	38
45	Validation of the Model for End-stage Liver Disease sodium (MELD-Na) score in the Eurotransplant region. American Journal of Transplantation, 2021, 21, 229-240.	2.6	37
46	Trajectories of Anxiety and Depression After Liver Transplantation as Related to Outcomes During 2-Year Follow-Up: A Prospective Cohort Study. Psychosomatic Medicine, 2018, 80, 174-183.	1.3	36
47	Study protocol for a multicenter randomized controlled trial to compare the efficacy of end-ischemic dual hypothermic oxygenated machine perfusion with static cold storage in preventing non-anastomotic biliary strictures after transplantation of liver grafts donated after circulatory death: DHOPE-DCD trial. BMC Gastroenterology, 2019, 19, 40.	0.8	36
48	Increased Mortality Among Patients With vs Without Cirrhosis and Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 940-947.e2.	2.4	36
49	Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. Journal of Hepatology, 2016, 65, 914-920.	1.8	35
50	Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. BMC Gastroenterology, 2010, 10, 144.	0.8	34
51	Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure. Hepatology, 1991, 14, 721-729.	3.6	34
52	Combined effect of donor and recipient risk on outcome after liver transplantation: Research of the Eurotransplant database. Liver Transplantation, 2015, 21, 1486-1493.	1.3	31
53	?-Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-?-2b in chronic hepatitis C non-responders. Liver International, 2007, 27, 070816165951003-???.	1.9	30
54	The price of donation after cardiac death in liver transplantation: a prospective cost-effectiveness study. Transplant International, 2013, 26, 411-418.	0.8	30

#	Article	IF	CITATIONS
55	Longitudinal Changes in BMD and Fracture Risk in Orthotopic Liver Transplant Recipients Not Using Bone-Modifying Treatment. Journal of Bone and Mineral Research, 2014, 29, 1763-1769.	3.1	30
56	Inadvertent arteriovenous stenting during transjugular intrahepatic portosystemic shunt procedure and the importance of hepatic artery perfusion. CardioVascular and Interventional Radiology, 1995, 18, 192-195.	0.9	27
57	Transarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials, 2012, 13, 144.	0.7	27
58	Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. Thrombosis and Haemostasis, 2007, 97, 181-185.	1.8	26
59	High peak alanine aminotransferase determines extra risk for nonanastomotic biliary strictures after liver transplantation with donation after circulatory death. Transplant International, 2015, 28, 492-501.	0.8	25
60	CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma. Journal of Pathology, 2018, 245, 297-310.	2.1	25
61	Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months. Clinical Gastroenterology and Hepatology, 2020, 18, 1609-1617.e4.	2.4	25
62	Chewing khat and chronic liver disease. Liver International, 2011, 31, 434-436.	1.9	24
63	Temporary heterotopic auxiliary liver transplantation for fulminant hepatitis B. Journal of Hepatology, 1995, 23, 109-118.	1.8	23
64	Recurrence of primary sclerosing cholangitis after liver transplantation – analysing the European Liver Transplant Registry and beyond. Transplant International, 2021, 34, 1455-1467.	0.8	23
65	Trajectories of anxiety and depression in liver transplant candidates during the waitingâ€iist period. British Journal of Health Psychology, 2017, 22, 481-501.	1.9	21
66	Evaluation of Liver Graft Donation After Euthanasia. JAMA Surgery, 2020, 155, 917.	2.2	21
67	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. Journal of Hepatology, 2022, 77, 84-97.	1.8	21
68	A prospective cohort study on posttraumatic stress disorder in liver transplantation recipients before and after transplantation: Prevalence, symptom occurrence, and intrusive memories. Journal of Psychosomatic Research, 2017, 95, 88-93.	1.2	20
69	Limited Sampling Model for Advanced Mycophenolic Acid Therapeutic Drug Monitoring After Liver Transplantation. Therapeutic Drug Monitoring, 2014, 36, 141-147.	1.0	19
70	Copeptin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival. Critical Care, 2017, 21, 321.	2.5	19
71	Role of age in presentation, response to therapy and outcome of autoimmune hepatitis. Clinical and Translational Gastroenterology, 2018, 9, e165.	1.3	19
72	Graves' hyperthyroidism in a patient with primary sclerosing cholangitis. Coincidence or combined pathogenesis?. European Journal of Gastroenterology and Hepatology, 1998, 10, 269-272.	0.8	18

#	Article	IF	CITATIONS
73	No beneficial effects of amantadine in treatment of chronic hepatitis C patients. Digestive and Liver Disease, 2010, 42, 496-502.	0.4	18
74	Matrix metalloproteinase 2 genotype is associated with nonanastomotic biliary strictures after orthotopic liver transplantation. Liver International, 2011, 31, 1110-1117.	1.9	18
75	Local but not systemic administration of mesenchymal stromal cells ameliorates fibrogenesis in regenerating livers. Journal of Cellular and Molecular Medicine, 2019, 23, 6238-6250.	1.6	18
76	Predictive Capacity of Risk Models in Liver Transplantation. Transplantation Direct, 2019, 5, e457.	0.8	18
77	Flexible Limited Sampling Model for Monitoring Tacrolimus in Stable Patients Having Undergone Liver Transplantation With Samples 4 to 6 Hours After Dosing Is Superior to Trough Concentration. Therapeutic Drug Monitoring, 2008, 30, 456-461.	1.0	17
78	Clinical value of myocardial perfusion scintigraphy as a screening tool in liver transplant candidates. Liver Transplantation, 2011, 17, 261-269.	1.3	17
79	No Association Between BMD and Prevalent Vertebral Fractures in Liver Transplant Recipients at Time of Screening Before Transplantation. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3677-3685.	1.8	17
80	Donorâ€specific antiâ€ <scp>HLA</scp> antibodies are not associated with nonanastomotic biliary strictures but both are independent risk factors for graft loss after liver transplantation. Clinical Transplantation, 2018, 32, e13163.	0.8	17
81	Mesenchymal stromal cells prevent progression of liver fibrosis in a novel zebrafish embryo model. Scientific Reports, 2018, 8, 16005.	1.6	17
82	Severe hepatitis and pure red cell aplasia in adult Still's disease: good response to immunosuppressive therapy. Digestive Diseases and Sciences, 1999, 44, 1639-1642.	1.1	16
83	Switching monitoring of emulsified cyclosporine from trough level to 2-hour level in stable liver transplant patients. Liver Transplantation, 2004, 10, 183-189.	1.3	16
84	Two Patients with Extremely Elevated Tumor Markers: Where Is the Malignancy?. Gastroenterology Research and Practice, 2011, 2011, 1-4.	0.7	16
85	High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. Liver International, 2020, 40, 2164-2171.	1.9	16
86	The Potentiating Effect of Ribavirin on Interferon in the Treatment of Hepatitis C: Lack of Evidence for Ribavirin-Induced Viral Mutagenesis. Antiviral Therapy, 2003, 8, 535-540.	0.6	16
87	Cytotoxic T Lymphocyte Antigen–4 +49A/G polymorphism does not affect susceptibility to autoimmune hepatitis. Liver International, 2013, 33, 1039-1043.	1.9	15
88	Biliary Complications After Liver Transplantation From Donation After Cardiac Death Donors. Annals of Surgery, 2015, 261, e64.	2.1	15
89	Copeptin as an Indicator of Hemodynamic Derangement and Prognosis in Liver Cirrhosis. PLoS ONE, 2015, 10, e0138264.	1.1	15
90	Donor hepatectomy time influences ischemia-reperfusion injury of the biliary tree in donation after circulatory death liverÂtransplantation. Surgery, 2020, 168, 160-166.	1.0	15

#	Article	IF	CITATIONS
91	The role of complement activation in autoimmune liver disease. Autoimmunity Reviews, 2020, 19, 102534.	2.5	15
92	Both muscle quantity and quality are predictors of waiting list mortality in patients with end-stage liver disease. Clinical Nutrition ESPEN, 2021, 42, 272-279.	0.5	15
93	Outcome of Liver Transplant Patients With High Urgent Priority: Are We Doing the Right Thing?. Transplantation, 2019, 103, 1181-1190.	0.5	14
94	Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients. Hepatology International, 2021, 15, 510-519.	1.9	14
95	Campylobacter jejuni peritonitis in a patient with liver cirrhosis. European Journal of Gastroenterology and Hepatology, 1996, 8, 1219-1221.	0.8	13
96	Use of a liver from donor after cardiac death: is it appropriate for the sick or the stable?. Current Opinion in Organ Transplantation, 2011, 16, 239-242.	0.8	13
97	Flushing the liver with urokinase before transplantation does not prevent nonanastomotic biliary strictures. Liver Transplantation, 2016, 22, 420-426.	1.3	13
98	Auxiliary or orthotopic liver transplantation forÂacute fatty liver of pregnancy: case series and review of the literature. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 1394-1398.	1.1	13
99	Identification and Validation of the Predictive Capacity of Risk Factors and Models in Liver Transplantation Over Time. Transplantation Direct, 2018, 4, e382.	0.8	13
100	Copeptin is an independent prognostic factor for transplantâ€free survival in cirrhosis. Liver International, 2016, 36, 530-537.	1.9	12
101	Hemodynamic response to primary prophylactic therapy with nonselective β-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis: a meta-analysis. European Journal of Gastroenterology and Hepatology, 2017, 29, 380-387.	0.8	12
102	<scp>MMP</scp> â€2 is a diseaseâ€modifying gene in primary sclerosing cholangitis. Liver International, 2014, 34, 274-280.	1.9	11
103	Value of Magnetic Resonance Cholangiopancreatography in Assessment of Nonanastomotic Biliary Strictures After Liver Transplantation. Transplantation Direct, 2015, 1, e42.	0.8	11
104	Optimizing the Use of Geriatric Livers for Transplantation in the Eurotransplant Region. Liver Transplantation, 2019, 25, 260-274.	1.3	11
105	Early Predictors of Shortâ€Term Prognosis in Acute and Acute Severe Autoimmune Hepatitis. Liver Transplantation, 2020, 26, 1573-1581.	1.3	11
106	Aminotransferases During Treatment Predict Long-Term Survival in Patients With Autoimmune Hepatitis Type 1: A Landmark Analysis. Clinical Gastroenterology and Hepatology, 2022, 20, 1776-1783.e4.	2.4	11
107	Preventive versus "on-demand―nutritional support during antiviral treatment for hepatitis C: A randomized controlled trial. Journal of Hepatology, 2012, 57, 1069-1075.	1.8	10
108	The center effect in liver transplantation in the Eurotransplant region: a retrospective database analysis. Transplant International, 2018, 31, 610-619.	0.8	10

#	Article	IF	CITATIONS
109	Liver retransplantation in adult recipients: analysis of a 38â€year experience in the Netherlands. Journal of Hepato-Biliary-Pancreatic Sciences, 2020, 27, 26-33.	1.4	10
110	Refitting the Model for End‣tage Liver Disease for the Eurotransplant Region. Hepatology, 2021, 74, 351-363.	3.6	10
111	Development and validation of a prognostic score for longâ€term transplantâ€free survival in autoimmune hepatitis type 1. United European Gastroenterology Journal, 2021, 9, 662-671.	1.6	10
112	Preanalytical Conditions and Circulating Matrix Metalloproteinases. Transplantation, 2005, 79, 745-746.	0.5	9
113	Liver test abnormalities predict complicated disease behaviour in patients with newly diagnosed Crohn's disease. International Journal of Colorectal Disease, 2017, 32, 459-467.	1.0	9
114	Current policy for allocation of donor livers in the Netherlands advantages primary sclerosing cholangitis patients on the liver transplantation waiting list-a retrospective study. Transplant International, 2018, 31, 590-599.	0.8	9
115	Impact of hepatic encephalopathy on liver transplant waiting list mortality in regions with different transplantation, 2018, 32, e13412.	0.8	9
116	The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030. Journal of Clinical Medicine, 2021, 10, 4562.	1.0	9
117	Elderly donor liver grafts are not associated with a higher incidence of biliary complications after liver transplantation: results of a national multicenter study. Clinical Transplantation, 2015, 29, 636-643.	0.8	8
118	Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. British Journal of Clinical Pharmacology, 2021, 87, 4262-4272.	1,1	8
119	Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study. PLoS ONE, 2016, 11, e0161821.	1.1	8
120	Liver Rupture after Transcatheter Arterial Chemoembolization of a Giant Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 1999, 10, 895-897.	0.2	7
121	Impact of Temporary Portocaval Shunting and Initial Arterial Reperfusion in Orthotopic Liver Transplantation, 2019, 25, 1690-1699.	1.3	6
122	Screening for abnormal glycosylation in a cohort of adult liver disease patients. Journal of Inherited Metabolic Disease, 2020, 43, 1310-1320.	1.7	6
123	Prognostic Importance of Increased Right Ventricular Afterload in Orthotopic Liver Transplantation Recipients With Endstage Cirrhosis. Heart Lung and Circulation, 2019, 28, 893-900.	0.2	5
124	Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study. Open Forum Infectious Diseases, 2021, 8, ofab006.	0.4	5
125	Joint modeling of liver transplant candidates outperforms the model for end-stage liver disease: The effect of disease development over time on patient outcome. American Journal of Transplantation, 2021, 21, 3583-3592.	2.6	5
126	Development and validation of a dynamic survival prediction model for patients with acute-on-chronic liver failure. JHEP Reports, 2021, 3, 100369.	2.6	5

#	Article	IF	CITATIONS
127	B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis. JHEP Reports, 2022, 4, 100460.	2.6	5
128	Antineutrophil Cytoplasmic Antibodies in Small-Duct Primary Sclerosing Cholangitis. Gastroenterology, 2009, 136, 364.	0.6	4
129	Use of thrombolytic therapy in DCD liver transplantation does not seem to improve outcome. American Journal of Transplantation, 2018, 18, 1029.	2.6	4
130	8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). Journal of Hepatology, 2019, 70, 554-557.	1.8	4
131	Selected liver grafts from donation after circulatory death can be safely used for retransplantation – a multicenter retrospective study. Transplant International, 2020, 33, 667-674.	0.8	4
132	Donor diabetes mellitus is a risk factor for diminished outcome after liver transplantation: a nationwide retrospective cohort study. Transplant International, 2021, 34, 110-117.	0.8	4
133	The role of the model for end-stage liver disease-sodium score and joint models for 90-day mortality prediction in patients with acute-on-chronic liver failure. Journal of Hepatology, 2021, 74, 475-476.	1.8	4
134	Does mucosal inflammation drive recurrence of primary sclerosing cholangitis in liver transplantion recipients with ulcerative colitis?. Digestive and Liver Disease, 2020, 52, 528-533.	0.4	3
135	Recipient's Genetic R702W NOD2 Variant Is Associated with an Increased Risk of Bacterial Infections after Orthotopic Liver Transplantation. PLoS ONE, 2013, 8, e72617.	1.1	3
136	The immunology of hepatic allograft rejection. Clinical Immunology Newsletter, 1990, 10, 69-73.	0.1	2
137	Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands. Journal of Medical Economics, 2021, 24, 1149-1163.	1.0	2
138	Oncofetal Protein CRIPTO Is Involved in Wound Healing and Fibrogenesis in the Regenerating Liver and Is Associated with the Initial Stages of Cardiac Fibrosis. Cells, 2021, 10, 3325.	1.8	2
139	LONG-TERM TREATMENT OF RECURRENT PERIHILAR NONANASTOMATIC BILIARY STRICTURES AFTER LIVER TRANSPLANTATION WITH EXPANDABLE METALLIC STENTS. Transplantation, 1995, 60, 399-400.	0.5	1
140	Effects of preventive versus "on-demand―nutritional support on paid labour productivity, physical exercise and performance status during PEG-interferon-containing treatment for hepatitis C. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 221-229.	0.7	1
141	Invited response to "MELD calibration― American Journal of Transplantation, 2021, 21, 440-441.	2.6	1
142	Calcineurin Inhibitors in the Treatment of Adult Autoimmune Hepatitis: A Systematic Review. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	1
143	Real-life data on the impact of successful downstaging in patients with hepatocellular carcinoma: A Dutch Multicenter Study. European Journal of Internal Medicine, 2022, 97, 56-61.	1.0	1
144	Editorial: genomeâ€wide association studies for developing chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2020, 52, 1083-1084.	1.9	1

BART VAN HOEK

#	Article	IF	CITATIONS
145	Hepato-biliary and Pancreatic Function. , 2005, , 247-283.		0
146	Gastric Variceal Hemorrhage in a Noncirrhotic Patient Treated with Balloon-Occluded Retrograde Transvenous Obliteration. CardioVascular and Interventional Radiology, 2015, 38, 1060-1063.	0.9	0
147	Short article. European Journal of Gastroenterology and Hepatology, 2017, 29, 535-538.	0.8	0
148	Utilizing Mechanistic Biomarkers in Treating Paracetamol Hepatotoxicity. Hepatology, 2018, 68, 2032-2035.	3.6	0
149	Comment on "The role of graft reperfusion sequence in the development of non-anastomotic biliary strictures following orthotopic liver transplantation: A meta-analysis― Hepatobiliary and Pancreatic Diseases International, 2019, 18, 401.	0.6	0
150	Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant. Clinical Genitourinary Cancer, 2019, 17, e893-e896.	0.9	0
151	The role of proportionate kinetic growth rate fraction in future remnant liver function over volume determined by 99mTc-Mebrofenin hepatobiliary scintigraphy including SPECT and computed tomography in the risk prediction of postoperative mortality in ALPPS. Surgery, 2019, 165, 1244-1245.	1.0	0
152	Sequential Liver Chemistry Profiling and Abdominal Ultrasound Assessments to Predict Biliary Strictures after Liver Transplantation. The Open Transplantation Journal, 2012, 6, 1-5.	0.1	0